Video
Advertise
Newsletter Signup
Podcast
Sign In
Aerospace
AI
Automotive
Cybersecurity
Energy
Gen Z
Industry 4.0
Operations
Software
Supply Chain
Site Map
2012
June
09
New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*
New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function
Page 1 of 1